Legal Representation
Attorney
Jonathan M. Gelchinsky
USPTO Deadlines
Application History
22 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 28, 2025 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Jul 28, 2025 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Mar 3, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 17, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Dec 16, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Dec 16, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 25, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Apr 30, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Apr 30, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 10, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Mar 22, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 23, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 23, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 23, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Dec 23, 2023 | GEAN | O | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | Loading... |
| Dec 23, 2023 | GEAP | F | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | Loading... |
| Dec 23, 2023 | EPEN | O | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY | Loading... |
| Dec 23, 2023 | CPEA | R | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED | Loading... |
| Dec 7, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 30, 2023 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Mar 29, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 13, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 035
Organizing and recruiting patients for clinical trials for the treatment of transthyretin (ATTR) amyloidosis using in vivo gene editing technology
Class 042
Scientific research in the nature of conducting clinical trials for the treatment of transthyretin (ATTR) amyloidosis using in vivo gene editing technology
Class 044
Medical treatment of transthyretin (ATTR) amyloidosis using in vivo gene editing technology
Additional Information
Design Mark
The mark consists of the word "MAGNITUDE" in red-orange, with the words "CLINICAL TRIAL" in gray appearing below the wording and a stylized design of the sun appearing above in shading from red-orange at the top to orange to yellow at the bottom.
Color Claim
The color(s) red-orange, orange, yellow and gray is/are claimed as a feature of the mark.
Classification
International Classes
035
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"CLINICAL TRIAL"